Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Interview
Spotlight Article

Brave new world – a new decade in allogeneic cellular immunotherapy

2020 vision - Tools and Technologies of Tomorrow

David Sourdive

David Sourdive is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016 and as Executive Vice President, Technical Operations until July, 2019. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.

DOI: 10.18609/cgti.2019.157
Citation: Cell & Gene Therapy Insights 2019; 5(12), 1523-1532.
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog